Fundraising Fox
Cytoseek
Bristol, GB · 2 known investors
Find your way into Cytoseek
Sign up to see every warm intro you have to Cytoseek
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cytoseek team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Hone Bio is a pre-clinical biotech company developing NanoPilot lipid nanoparticle (LNP) targeting technology for extrahepatic drug delivery, engineering LNPs to target specific cell types while blocking off-target liver uptake. It serves therapeutic developers seeking to deliver treatments such as mRNA-based therapies beyond the liver.
Founders & leadership
BC
Ben CarterChief Executive OfficerCEO and co-founder of Hone Bio, a biotech company developing lipid nanoparticle targeting technology for extrahepatic drug delivery in mRNA and gene therapy applications.
Investors · 2
Future Planet Capitallisted by Future Planet CapitalLondon
How we know: Future Planet Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Parkwalk AdvisorsreportedLondon
How we know: a partner's Signal profile · Not right? Tell us
Frequently asked questions
- What does Cytoseek do?
- Hone Bio is a pre-clinical biotech company developing NanoPilot lipid nanoparticle (LNP) targeting technology for extrahepatic drug delivery, engineering LNPs to target specific cell types while blocking off-target liver uptake. It serves therapeutic developers seeking to deliver treatments such as mRNA-based therapies beyond the liver.
- Who are Cytoseek's investors?
- Cytoseek's investors include Future Planet Capital, Parkwalk Advisors.
- Where is Cytoseek headquartered?
- Cytoseek is headquartered in Bristol, GB.